BDA-366
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 407377

CAS#: 1909226-00-1

Description: BDA-366 is a BCL2-BH4 antagonist. BDA-366 suppresses human myeloma growth. BDA-366 induces robust apoptosis in MM cell lines and primary MM cells by inducing BCL2 conformational change. Delivery of BDA-366 substantially suppressed the growth of human MM xenografts in NOD-scid/IL2Rγnull mice, without significant cytotoxic effects on normal hematopoietic cells or body weight. Thus, BDA-366 functions as a novel BH4-based BCL2 inhibitor and offers an entirely new tool for MM therapy.


Chemical Structure

img
BDA-366
CAS# 1909226-00-1

Theoretical Analysis

MedKoo Cat#: 407377
Name: BDA-366
CAS#: 1909226-00-1
Chemical Formula: C24H29N3O4
Exact Mass: 423.22
Molecular Weight: 423.513
Elemental Analysis: C, 68.06; H, 6.90; N, 9.92; O, 15.11

Price and Availability

Size Price Availability Quantity
5mg USD 250 2 Weeks
10mg USD 450 2 Weeks
25mg USD 750 2 Weeks
Bulk inquiry

Related CAS #: 1821496-27-8; 1909226-00-1  

Synonym: BDA-366; BDA 366; BDA366.

IUPAC/Chemical Name: 1-(((S)-3-(diethylamino)-2-hydroxypropyl)amino)-4-((((S)-oxiran-2-yl)methyl)amino)anthracene-9,10-dione

InChi Key: JYOOEVFJWLBLKF-HOTGVXAUSA-N

InChi Code: InChI=1S/C24H29N3O4/c1-3-27(4-2)13-15(28)11-25-19-9-10-20(26-12-16-14-31-16)22-21(19)23(29)17-7-5-6-8-18(17)24(22)30/h5-10,15-16,25-26,28H,3-4,11-14H2,1-2H3/t15-,16-/m0/s1

SMILES Code: CCN(CC)C[C@@H](O)CNC1=CC=C(NC[C@@H]2OC2)C3=C1C(C4=C(C3=O)C=CC=C4)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 423.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Deng J, Park D, Wang M, Nooka A, Deng Q, Matulis S, Kaufman J, Lonial S, Boise LH, Galipeau J, Deng X. BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth. Oncotarget. 2016 May 10;7(19):27753-63. doi: 10.18632/oncotarget.8513. PubMed PMID: 27049723; PubMed Central PMCID: PMC5053685.

2: Han B, Park D, Li R, Xie M, Owonikoko TK, Zhang G, Sica GL, Ding C, Zhou J, Magis AT, Chen ZG, Shin DM, Ramalingam SS, Khuri FR, Curran WJ, Deng X. Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy. Cancer Cell. 2015 Jun 8;27(6):852-63. doi: 10.1016/j.ccell.2015.04.010. PubMed PMID: 26004684; PubMed Central PMCID: PMC4470473.

3: Vervloessem T, La Rovere R, Bultynck G. Antagonizing Bcl-2's BH4 domain in cancer. Aging (Albany NY). 2015 Oct;7(10):748-9. PubMed PMID: 26525307; PubMed Central PMCID: PMC4637201.

4: Liu Z, Wild C, Ding Y, Ye N, Chen H, Wold EA, Zhou J. BH4 domain of Bcl-2 as a novel target for cancer therapy. Drug Discov Today. 2016 Jun;21(6):989-96. doi: 10.1016/j.drudis.2015.11.008. Review. PubMed PMID: 26631752; PubMed Central PMCID: PMC4882289.

5: Selective Inhibition of BCL2 Shows Antitumor Effects in Lung Cancer. Cancer Discov. 2015 Jul;5(7):OF21. doi: 10.1158/2159-8290.CD-RW2015-102. PubMed PMID: 26045015.